Marked responses to pemetrexed chemotherapy for metastatic adenocarcinoma of the parotid gland: Case series.
Paul V ViscuseKatharine PricePublished in: Head & neck (2019)
To our knowledge, this is the first report of efficacy of single-agent pemetrexed for metastatic salivary gland adenocarcinoma. Given the significant and sustained responses in heavily pretreated patients, further investigation of pemetrexed for salivary cancer may be warranted.
Keyphrases
- small cell lung cancer
- squamous cell carcinoma
- locally advanced
- end stage renal disease
- advanced non small cell lung cancer
- ejection fraction
- newly diagnosed
- healthcare
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- papillary thyroid
- radiation therapy
- young adults
- epidermal growth factor receptor
- squamous cell
- tyrosine kinase